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Abstract
Infectious bursal disease virus (IBDV) causes economically important immunosuppressive disease in young chickens. The self-
assembling capsid protein (VP2) from IBDV strain IR01 was expressed in Pichia pastoris resulting in the formation of
homomeric, 23-nm infectious bursal disease subviral particles (IBD-SVPs) with a yield of 76 mg/l before and 38 mg/l after
purification. Anti-IBDV antibodies were detected in chickens injected with purified IBD-SVPs or fed with either purified IBD-
SVPs or inactivated P. pastoris cells containing IBD-VP2 (cell-encapsulated). Challenge studies using the heterologous
classical IBDV strain (MB3) showed that intramuscular vaccination with 20 mg purified IBD-SVPs conferred full protection,
achieved complete virus clearance and prevented bursal damage and atrophy, compared with only 40% protection, 0–10%
virus clearance accompanied by severe atrophy and substantial bursal damage in mock-vaccinated and challenge controls.
The commercial IBDV vaccine also conferred full protection and achieved complete virus clearance, albeit with partial bursal
atrophy. Oral administration of 500 mg purified IBD-SVPs with and without adjuvant conferred 100% protection but
achieved only 60% virus clearance with adjuvant and none without it. Moderate bursal damage was observed in both cases
but the inclusion of adjuvant resulted in bursal atrophy similar to that observed with live-attenuated vaccine and parenteral
administration of 20 mg purified IBD-SVPs. The oral administration of 250 mg P. pastoris cells containing IBD-VP2 resulted in
100% protection with adjuvant and 60% without, accompanied by moderate bursal damage and atrophy in both groups,
whereas 25 mg P. pastoris cells containing IBD-VP2 resulted in 90–100% protection with moderate bursal lesions and severe
atrophy. Finally, the oral delivery of 50 mg purified IBD-SVPs achieved 40–60% protection with severe bursal lesions and
atrophy. Both oral and parenteral administration of yeast-derived IBD-VP2 can therefore induce a specific and protective
immune response against IBDV without affecting the growth rate of chickens.
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Introduction
Infectious bursal disease virus (IBDV) serotype I is an immunosup-
pressive virus (genus Avibirnavirus, family Birnaviridae) that causes
significant morbidity and mortality in young chickens. The virus is
stable in the presence of disinfectants [1] and is transmitted via the
oral-fecal route [2,3]. When susceptible chickens are infected,
IBDV replicates in gut-associated macrophages and lymphoid
cells, allowing it to reach the bursa of Fabricius (BF). The virus
predominantly targets maturing B lymphocytes in the BF [4] via
a4b1 integrin [5]. IBDV induces apoptosis in the peripheral
lymphocytes [6] and causes severe immunosuppression and often
death in chickens that are 3–6 weeks old, when the BF is in its
critical development stage [7].
Infected chickens become susceptible to other diseases and their
response to vaccination declines. Younger chickens are passively
protected by maternal antibodies transmitted via the egg yolk [8]
whereas older ones can produce antibodies against the virus and
only rarely develop clinical signs of the disease. The clinical signs
include distress, depression, diarrhea, anorexia, ruffled feathers,
trembling and dehydration, usually appearing 2 days after
infection and declining by day 4 due to the rapid recovery of
survivors [9].
There is no specific treatment for IBD and currently the disease
is controlled by administering attenuated or inactivated IBDV as a
vaccine [2]. Attenuated vaccines are usually administered orally in
drinking water, whereas inactivated vaccines are administrated by
intramuscular injection.
IBDV has two serotypes but only serotype 1 is pathogenic in
chickens. Within this serotype, classical and antigenically-distinct
variant strains can be distinguished. The ‘‘very virulent’’ (vv)
strains that have been circulating since the late 1980s in Europe,
Africa, and Asia are antigenically similar to the classical strains [3].
Virus-neutralization tests can also distinguish several further
subtypes [10]. The prevalence of vv strains probably reflects the
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selection pressure caused by vaccination [11], hence conventional
vaccines are now unable to provide full protection [12]. Most live
vaccines are based on classical virulent strains and are classified as
‘‘mild’’ vaccines with low protective efficiency against vv strains.
Intermediate and intermediate plus or ‘‘hot’’ vaccines confer better
protection, but they do not provide complete protection and may
also induce moderate to severe clinical signs and immunosup-
pression [13,14]. Therefore, only mild and intermediate viruses
are used as attenuated virus vaccines [15]. Inactivated vaccines are
expensive to produce and deliver, and they only provide weak
protection [16]. However, they are used to induce high levels of
antibodies in breeder hens, so that chickens are protected by
maternal antibodies for a considerable time. In this case, it is
crucial to identify the optimal time point for vaccination to boost
protective immune responses without interfering with the maternal
antibodies [17]. The development of novel and efficacious
vaccines against vv strains is therefore essential. Genetically
engineered viral vectors have been used successfully to induce
T-cell as well as B-cell immunity without interfering with maternal
antibodies [1]. Also, in contrast to conventional vaccines,
recombinant subunit vaccines do not by design include genetic
material and can therefore induce a protective immune response
but are unable to revert to virulence.
IBDV has a non-enveloped icosahedral capsid with a T=13
surface lattice and a linear double stranded RNA genome in two
segments, named A and B. Segment B encodes an RNA-
dependent RNA polymerase, and segment A contains two partly
overlapping open reading frames (ORFs) encoding the non-
structural protein VP5 (which facilitates virus dissemination [18])
and a larger polyprotein that is autocatalytically cleaved into the
structural proteins VP2 and VP3, and the serine protease VP4
[9,19,20]. VP2 is the major IBDV antigen, which includes a
conformational epitope that can induce the production of virus-
neutralizing antibodies [21]. VP2 is also responsible for antigenic
variation, virulence and tissue culture adaptation [22]. When VP2
is produced in heterologous cells, the recombinant protein can
aggregate to form symmetrical, multimeric subviral particles
(SVPs) with enhanced immunogenicity.
VP2 has been expressed in several heterologous systems with
different degrees of success. Bacterial systems such as Escherichia coli
produce non-immunogenic SVPs [23,24]. However, yeasts such as
Saccharomyces cerevisiae [23] and Pichia pastoris [25], baculovirus-
infected insect cell lines such as SF9 [26] and High-Five [27], and
baculovirus-infected insects such as cabbage looper larvae
(Trichoplusia ni) [28], can produce SVPs that confer protection
following parenteral administration, albeit after extensive purifi-
cation. In contrast, plants such as Arabidopsis thaliana [29] and rice
[16] can produce recombinant VP2 suitable for direct oral delivery
without purification, although this does not achieve complete
protection probably because of the inefficient assembly of IBD-
SVPs in plant cells.
Oral vaccine delivery is simple and inexpensive, but orally-
delivered subunit vaccines tend to have limited and short-lived
immunogenicity that must be addressed by boost regimes and/or
the co-administration of adjuvants. We previously described the
production of IBD-SVPs in P. pastoris [30]. Here we report the oral
delivery of yeast-derived recombinant IBD-VP2 from the vv strain
IR01 [31] to young chickens. The vaccine was applied using boost
regimes comprising either a cell-encapsulated vaccine (inactivated
freeze-dried P. pastoris cells containing IBD-VP2) or purified IBD-
SVPs alone or in combination with an oral adjuvant mixture
comprising CpG oligonucleotides (CpG ODNs) and NaF [32]. We
found that these candidate vaccines conferred partial or full




The IBDV-VP2 cDNA from strain IR01 (GenBank accession
number AY704912 [31]) was used as a template and the sequence
corresponding to the mature IBD-VP2 was amplified using a two-
step PCR procedure. In the first step, an overhang was introduced
onto the 59-end of the sequence using forward primer 59-TTT
ATA AAA AAA AAA AAA AC-39 and a His6-tag was introduced
onto the 39-end using reverse primer 59-GCT CTA GAT TTA
GTG ATG GTG ATG GTG ATG TGC TCC TGC AAT CTT
CAG-39. In the second step, the Petroselinum hortense chalcone
synthase 59 untranslated region was introduced upstream of the
IBD-VP2 cDNA using an overlapping complementary primer (59-
CGC GAA TTC ACA ACA CAA ATC AGA TTT ATA GAG
AGA TTT ATA AAA AAA AAA AAA AC-39) and the same
reverse primer. The product was transferred to the expression
vector pPICZ_B (Invitrogen, Karlsruhe, Germany) using the
EcoRI and XbaI restriction sites (underlined) placing it under the
control of the methanol-inducible alcohol oxidase (AOX1)
promoter (Figure 1). The recombinant vector was introduced into
P. pastoris strain X-33 (Invitrogen) as previously described [33] to
yield the recombinant strain Pichia IBD-VP2.
IBD-VP2 expression, extraction and purification
Recombinant yeast cells were cultured in YPD medium (1% (w/
v) yeast extract, 2% (w/v) peptone and 2% (w/v) dextrose) as
recommended (EasySelectTM Pichia Expression Kit, Invitrogen).
IBD-VP2 expression was induced by resuspending the cells to
OD600nm=1.0 in BMMY medium (100 mM sodium phosphate,
pH 6.0, 1% (w/v) yeast extract, 2% (w/v) peptone, 1.34% (w/v)
yeast nitrogen base, 0.4 mg/ml biotin) containing 0.5% (v/v)
methanol. The most productive colony was identified by
immunoblotting, and was cultured in 500 ml BMMY medium
for 4 days as recommended (Invitrogen). Methanol was added to a
final concentration of 0.5% (v/v) on the second day and increased
to 1% (v/v) on the third and fourth days. The cells were then
harvested by centrifugation at 3,0006g for 5 min at room
temperature, resuspended in breaking buffer (100 mM sodium
acetate, pH 4.0, 1 mM PMSF, 1 mM EDTA, 5% (v/v) glycerol)
and disrupted by five passes in a microfluidizer (Newton, MA,
USA). The supernatant was collected after centrifugation at
13,0006g for 30 min at room temperature, IBD-VP2 was
precipitated using 50% ammonium sulfate and resuspended in
5 ml phosphate-buffered saline (PBS). The purified sample was
polished and simultaneously characterized by size exclusion
chromatography (SEC) on a Hiprep 26/60 Sephacryl S400 HR
column (GE HealthCare, Freiburg, Germany). The IBD-SVP
elution fractions were concentrated using a Vivaspin 20 spin
column with a 300-kDa cut-off membrane (Sartorius-Stedim,
Go¨ttingen, Germany). The purity of the IBD-SVPs was deter-
mined by the densitometric analysis of polyacrylamide gels stained
with Coomassie Brilliant Blue, using AIDA image analysis
software. The protein content was determined using the BCA
assay kit (Thermo Scientific, Dreieich, Germany).
SDS-PAGE and immunoblotting
The protein samples were separated by SDS-PAGE (12% (w/v)
polyacrylamide), transferred to a nitrocellulose membrane and
blocked in 5% (w/v) skimmed milk in PBS containing 0.05% (v/v)
Tween 20 (PBST). Recombinant IBD-VP2 was detected with a
Protective Oral Vaccination against IBDV
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rabbit anti-VP2 [27] primary antibody (diluted 1:10,000) kindly
provided by Prof. Wang (National Chung Hsing University,
Taichung, Taiwan), and an alkaline phosphatase-conjugated goat
anti-rabbit secondary antibody (Dianova, Hamburg, Germany)
diluted to 0.2 mg/ml. Each reaction was carried out for 1 h at
room temperature with gentle agitation. After three 5-min washes
in PBST, the signal was detected with NBT/BCIP (Biorad,
Mu¨nchen, Germany).
Transmission electron microscopy
IBD-SVPs images were acquired by applying 30-ml aliquot
samples onto discharged 400 mesh carbon-coated nickel grids
(Plano, Wetzlar, Germany) for 15 min at room temperature.
Excess particles were removed by rinsing with PBS. The grids
were negatively stained with 2% (w/v) aqueous uranyl acetate and
observed under a 400T electron microscope (Philips, Eindhoven,
the Netherlands) operated at 60 kV accelerating voltage. Digital
images were captured with an Olympus camera (MORADA) and
processed using iTEM software (Mu¨nster, Germany).
Animals
Specific pathogen free (SPF) eggs from white Leghorn chickens
were purchased from Lohmann Tierzucht (Cuxhaven, Germany).
Hatched chickens were kept under SPF conditions in isolators
under positive filtered air pressure and were provided with free
access to standard food and drinking water. The bodyweight (BW)
gain and health of the chickens were monitored before infection
twice daily and after infection six times daily throughout the
experiment.
Immunization and sampling
Ethics statement: The animal experiments were officially
approved by the Landesamt fu¨r Gesundheit und Soziales,
reference number G 289/10. All animals received humane care
in accordance with the requirements of the German Tierschutz-
gesetz and the European Commission guidelines on the accom-
modation and care of animals used for experimental and other
scientific purposes. Following infection, birds were humanely
euthanized if they were not able to reach feeders and drinkers, and
were counted as disease mortality. The survivors were also
euthanized one week after infection. No analgesics or anesthetics
were used before euthanization. Birds were stunned by a blow to
the head and killed by dislocation of the neck or by cutting the
vena jugularis.
Sixty-five 14-day-old chickens were marked individually and
randomly divided into 13 experimental groups of five individuals,
and were maintained in separate isolators as follows: isolator 1 –
groups 1, 2, 3 and 4; isolator 2 – groups 5, 6, 7 and 8; isolator 3 –
groups 9, 10 and 11; isolator 4 – group 12; isolator 5 – group 13.
The chickens were immunized four times at weekly intervals as
shown in Table 1. For oral immunization, the freeze-dried
inactivated yeast cells expressing the IBD-VP2 protein, and the
purified IBD-SVPs, were administered as shown in Table 1. Prior
to immunization, the freshly harvested cell suspensions were
inactivated by applying two thermal cycles at 70uC and 15uC,
each for 5 min. The suspensions were supplemented with 50 mg
CpG oligodeoxynucleotides plus NaF (100 mg per kg body weight
at the time of vaccination) as an oral adjuvant. The freeze-dried
cell-encapsulated vaccine was applied in 250-mg and 25-mg doses
with and without adjuvant mixture in 1 ml drinking water.
Purified IBD-SVPs were applied in 500-mg and 50-mg doses with
and without adjuvant in 0.5 ml PBS. As a control, 250 mg of
freeze-dried inactivated wild-type P. pastoris cells was applied to
group 9.
Oral immunization was achieved by oral gavage into the crop.
The attenuated virus preparation AviPro Gumboro vac (Lohmann
Animal Health GmbH & Co. KG, Cuxhaven) was also applied
orally as a positive control, according to the manufacturer’s
instructions.
Parenteral immunization was achieved by the intramuscular
injection of 20 mg purified IBD-SVPs combined with 20 ml
Adjuvant 100 (Gerbu, Wieblingen) in a total volume of 100 ml.
Two groups of chickens were not vaccinated and were used as
negative controls in the viral challenge (group 11) and vaccine
(group 13) experiments, respectively.
Serum antibody responses in immunized chickens
Blood samples were collected from the wing vein of immunized
chickens at different time points (Table 1) and the IBD-VP2-
specific IgM and IgY antibody responses in the sera were
measured by indirect ELISA. The purified yeast-derived IBD-
SVPs were coated onto 96-well microtiter plates (10 mg/ml in
PBS) overnight at 4uC. The plates were blocked with 2.5% (w/v)
skimmed milk in 16 PBS containing 0.05% (v/v) Tween 20
(PBST) for 1 h at room temperature. After three washes with
PBST, the plates were incubated with 100 ml serum samples
(diluted 1:50 in PBS) for 2 h at room temperature. After three
further washes, IgY and IgM were detected with 2 mg/ml
horseradish peroxidase-conjugated rabbit anti-chicken IgY (Gen-
taur, Aachen, Germany) or 5 mg/ml horseradish peroxidase-
conjugated goat anti-chicken IgM (Gentaur). Bound secondary
antibodies were detected using the ABTS substrate and quantified
on a microplate reader at 405 nm. A response was considered
positive if the mean absorbance was more than twice that of the
pre-immune sera plus two standard deviations (.0.2).
The anti-IBD titer was also determined using a commercial
antibody ELISA test kit (IDEXX IBD-XR Ab test, Westbrook,
ME, USA). This kit is often used in chicken farms to evaluate
immunity against IBDV by testing the serum antibody titer against
Figure 1. Pichia pastoris expression cassette in pPICZ_B (Invitrogen). Abbreviations: 59AOX1 and AOX1 TT, methanol-inducible alcohol
oxidase 1 gene promoter and terminator, respectively; CHS 59-UT, untranslated region of the Petroselinum hortense chalcone synthase gene; IBD-VP2,
cDNA of Infectious bursal disease virus protein 2, corresponding to the first 441 amino acids; H6, His-6 tag for detection and purification; pTEF1,
transcription elongation factor 1 gene promoter from S. cerevisiae that drives expression of the Sh ble gene in P. pastoris conferring zeocin resistance;
pEM7, constitutive synthetic prokaryotic promoter that drives expression of the Sh ble gene in E. coli; Sh ble, Streptoalloteichus hindustanus bleomycin
resistance gene; Cyc1 TT, CYC1 transcription termination region (GenBank accession number M34014), the 39 end of the S. cerevisiae CYC1 gene that
allows efficient 39 mRNA processing of the Sh ble gene for increased stability.
doi:10.1371/journal.pone.0083210.g001
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the virus. The method is an indirect ELISA and titers above 396
are considered positive.
Challenge experiments and post-challenge studies
Chickens were challenged with the classical IBDV strain MB3
from a recent outbreak in Germany. This strain does not grow well
in embryonated SPF eggs and is not cell culture adapted, so birds
were infected via the ocular route with 0.1 ml homogenized bursa
of Fabricious (BF) from naturally infected chickens, passed through
a 0.2-mm filter. The samples were kindly provided by Dr.
Hermann Block [17]. All chickens except those in group 13 were
challenged with the virus when they were 42 days old. Clinical
signs and mortality were recorded for one week after the challenge.
The birds were then killed and the BF isolated to determine BF/
BW ratios.
Histopathological studies
The BFs from all 65 animals were fixed in phosphate buffer
containing 10% (v/v) formalin, embedded in paraffin and
sectioned. The sections were stained with hematoxylin and eosin.
Bursa lesion scores were determined using a light microscope and
comparison between groups [17] as previously described [34]:
score 0, no bursal damage or lesion in any follicle, clear
demarcation of medulla and cortex; score 1, mild necrosis and
mild lymphocyte depletion in a few follicles with overall bursal
architecture maintained; score 2, moderate atrophy or lymphocyte
depletion in one third to one half of the follicles, aggregation of
heterophils, macrophages, and hyperplasia of epithelial reticular
cells with some vacuole-like structures; score 3, more than half of
the follicles show severe necrosis, atrophy and lymphocyte
depletion, and loss of the outline of follicular architecture such
that it is replaced with proliferating connective tissue and
fibroplasias.
Virus clearance assay
The presence of the IBDV antigen in the BF was analyzed by
sandwich ELISA as previously described [24] with some
modifications. Briefly, the wells of a flat-bottom 96-well microtiter
plate were coated overnight at 4uC with 10 mg/ml mouse anti-
IBD-VP2 antibody (Ingenasa, Madrid, Spain). The wells were
washed with PBST, blocked by adding 150 ml/well 2.5% (w/v)
skimmed milk in PBST and incubated for 1 h at room
temperature. The BF was ground and diluted 1:1 (w/v) in PBS
and 100 ml of the homogenate was added to the wells. The plate
was incubated overnight at 4uC before adding 100 ml rabbit anti-
IBD-VP2 (diluted 1:10,000 in PBST) and incubating for 1 h at
room temperature. After washing again, we added 100 ml
horseradish peroxidase-conjugated goat anti-rabbit secondary
antibody diluted to 0.12 mg/ml (Dianova, Hamburg, Germany).
The bound antibodies were detected using ABTS substrate and
the absorbance was read at 405 nm on a microplate reader.
Values greater than 0.2 were considered positive.
Statistical analysis
Statistical analysis was carried out using SPSS v15 software
(SPSS Inc., Chicago, IL, USA). Each chicken was considered as an
experimental unit. The significance level (a) was set to 0.05. The
normality of the data and the homogeneity of variances were
assessed using Shapiro-Wilk’s and Levene’s tests, respectively. The
collected data were subjected to one-way analysis of variance
(ANOVA) followed by Duncan’s test at significance level of
p,0.05.
Results
Production of IBD-VP2 in Pichia pastoris
The 1323-bp mature IBD-VP2 cDNA sequence was amplified
from IBDV strain IR01 and transferred to the pPICZ_B vector,
containing a C-terminal His6-tag sequence for protein detection
and purification. The vector was linearized and introduced into P.
pastoris cells, resulting in the insertion of the transgene at the AOX1
locus. The recombinant yeast cells were then induced with
methanol, and immunoblot analysis confirmed the presence of a
40-kDa VP2 band (Figure 2A) and a further band larger than
170 kDa that appeared because of the hydrophobic nature of the
IBD-VP2 protein. The recombinant protein accumulated at levels
of up to 76 mg/l of the culture after 96 h expression induction
(Figure 2B).
Purification and characterization of IBD-VP2
An acidic extraction buffer (pH 4.0) allowed the recovery of
60% of the IBD-VP2 protein at a purity of 75%. Subsequent
ammonium sulfate precipitation improved the purity of IBD-VP2
to 90% without substantial further loss. The remaining IBD-VP2
was purified further and simultaneously characterized by size
exclusion chromatography (SEC). The eluent was collected in 2-ml
fractions and a 10-ml sample from each fraction was analyzed by
ELISA to determine the VP2 content. Two major peaks were
detected by ELISA at 152 and 250 ml of the elution volume, both
of which contained high and low molecular mass fractions of IBD-
VP2 (Figure 3). Neither of these peaks was present in the wild-type
Pichia X-33 cell extract purified under the same conditions (data
not shown). Electron microscopy revealed that the 152-ml peak
contained larger (23 nm) fully-assembled IBD-SVPs with a T=1
lattice (Figure 3C) as previously described [35,36], whereas
symmetrical structures were not detected in the 250-ml peak.
Fractions representing the 152-ml peak were collected, mixed and
concentrated using nanosep centrifugal device with a 300-kDa
molecular weight cut off (MWCO). As we previously reported
Figure 2. Characterization of recombinant IBD-VP2 produced
in Pichia pastoris. (A) A 12-ml aliquot of the P. pastoris cell lysate was
separated by SDS-PAGE (12% (w/v) polyacrylamide) and blotted onto a
nitrocellulose membrane. The antigen was detected using a rabbit anti-
IBD-VP2 (1:10,000) primary antibody and an alkaline phosphatase-
conjugated goat anti-rabbit secondary antibody (0.12 mg/ml). The
signal was detected with NBT/BCIP for 5 min at room temperature.
(B) Intracellular accumulation level of IBD-VP2 in P. pastoris cultures
following expression induction. Biological triplicates were used for each
experiment.
doi:10.1371/journal.pone.0083210.g002
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[30], 38 mg of IBD-SVPs with .95% purity was extracted from
the cells harvested from 1 l of culture using an acidic buffer,
followed by ammonium sulfate precipitation and SEC.
Recombinant yeast cells expressing IBD-VP2 were heat-
inactivated, freeze-dried and ground to a fine powder as described
above, and the IBD-SVPs were extracted and purified. Immuno-
blot analysis and SEC confirmed that IBD-VP2 remains stable
during these treatments and the integrity of IBD-SVPs are
maintained (Figure 4). We also calculated that 1 mg of freeze-
dried yeast powder contains approximately 16 mg of VP2 (data not
shown). The cell powder was stored at +4uC prior to immuniza-
tion.
Chicken immunization and serum antibody response
Two-week-old SPF chickens were immunized with purified
IBD-SVPs or cell-encapsulated IBD-VP2 proteins. For each form
of the antigen, two different doses were administered with and
without adjuvant. The commercial attenuated IBDV vaccine
Avipro Gumboro vac was used as a positive control, and
inactivated freeze-dried wild-type P. pastoris cells were used as a
negative control. The powdered cells were resuspended in 1 ml
drinking water and the adjuvant, where required, was added
immediately before administration. Two groups remained unvac-
cinated (groups 11 and 13) and one group received an
intramuscular injection of the purified antigen (group 10).
Vaccination was carried out weekly for 4 weeks followed by viral
challenge (Figure 5A). The serum samples were collected before
each immunization and challenge, and when the chickens were
sacrificed for analysis.
Serum IgM and/or IgY induced by the vaccine and/or virus
were detected by ELISA as shown in Figure 5B–C and Table 2.
An IgM response before challenge was only detected in the
chickens from group 10, which received the intramuscular vaccine,
whereas this response appeared in all other chickens following viral
challenge. In contrast, an IgY response was detected in groups 10
and 12 as well as groups that received 50 mg purified IBD-SVPs
without adjuvant (group 5) and 500 mg purified IBD-SVPs with
adjuvant (group 8) before challenge. The IgY response was
comprehensive and potent in chickens from group 10 (intramus-
cular vaccine) and group 12 (oral attenuated virus).
Following virus challenge, chickens from groups 8, 10 and 12 as
well as those that received 250 mg freeze-dried yeast cells
containing IBD-VP2 with adjuvant (group 2) were protected from
the virus and showed a positive IgY response. Although all
chickens in the groups receiving 25 mg freeze-dried yeast cells
containing IBD-VP2 (group 3) and 500 mg purified IBD-SVPs
both without adjuvant (group 7) were fully protected, only 80%
were IgY seropositive, and the remaining 20% were instead IgM
seropositive. However, in other groups, some IgM seropositive but
IgY seronegative chickens were not protected. Indeed, all surviving
birds were seropositive in the IDEXX ELISA indicating that this
method evaluates positive response resulting from either IgM or
IgY.
Health status and clinical signs
Weight gain during the experiment was monitored as a health
index. No significant difference (p.0.05) in weight gain was
Figure 3. Separation of partially-purified yeast-derived IBD-
VP2 by SEC and analysis by electron microscopy studies. (A)
The IBD-VP2 protein was produced and extracted from the P. pastoris
cells using breaking buffer (pH 4.0) followed by precipitation with 50%
ammonium sulfate. The protein pellet was resuspended in PBS and
separated by SEC using a S-400 HR column with a size separation range
20–8000 kDa. (B) The eluted fractions were tested for IBD-VP2 content
using an indirect ELISA, revealing IBD-VP2 peaks at 152 and 250 ml
during SEC. Electron microscopy revealed that only the 152-ml peak
contained fully-assembled 23-nm IBD-SVPs. Scale bar = 50 nm.
doi:10.1371/journal.pone.0083210.g003
Figure 4. Analysis of IBD-SVP stability and integrity after yeast
cell inactivation using SDS-PAGE and SEC. We separated 12-ml
samples by SDS-PAGE (12% (v/w) polyacrylamide) followed by staining
with Coomassie Brilliant Blue (A) and immunoblot detection (B) using a
rabbit anti-VP2 primary antibody, an alkaline phosphatase-conjugated
goat anti-rabbit secondary antibody (0.2 mg/ml) and NBT/BCIP to detect
the signal: (1) purified IBD-SVPs derived from freeze-dried inactivated P.
pastoris cells; (2) purified IBD-SVPs derived from active freeze-dried P.
pastoris cells; (3) purified IBD-SVPs as a positive control. (C)
Chromatogram obtained by separation of the corresponding samples
using a SEC S-400 HR column and A¨kta Explorer.
doi:10.1371/journal.pone.0083210.g004
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Figure 5. Immunization of chickens with IBD-VP2 or purified IBD-SVPs produced in P. pastoris. (A) Immunization scheme: two-week-old
chickens were immunized at the indicated times (schematized as black bars) by either oral (groups 1–9 and 12) or intramuscular (group 10)
administration. Oral immunization was carried out using different doses of either freeze-dried yeast (groups 1–4) or purified yeast-derived IBD-SVPs
(groups 5–8) with and without an oral adjuvant mixture. Wild-type P. pastoris X-33 cells were used as a negative control (group 9) and Avipro
Gumboro vac was used as a positive control (group 12). Intramascular immunization was carried out using 20 mg of purified yeast-derived IBD-SVPs
mixed with Adjuvant 100 (Gerbu). Two groups remained unvaccinated, one in the challenge experiment and used as a challenge control (group 11)
and the other unchallenged as a vaccine control (group 13). The gray bar indicates the time interval following viral challenge; arrows indicate the
time of death. The reactivity of chicken sera IgM (B) and IgY (C) with IBD-SVPs was determined by ELISA. The serum samples were collected before
immunization, before viral challenge and one week after challenge. The mean of absorbance at 405 nm is shown for five chickens in each group with
standard error indicated by error bars. The 0.2 OD value was used as a cut off; chickens with a higher antibody titer were considered seropositive.
doi:10.1371/journal.pone.0083210.g005
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observed among the groups during the immunization phase,
which indicates that the vaccine did not interfere with normal
growth (data not shown). Typical IBD clinical signs such as ruffled
feathers, depression, abnormal feces and mortality were assessed
daily following the challenge. Birds in the groups received
intramascular vaccine (group 10) as well as those received live
vaccine (group 12) showed no clinical sign following challenge.
Clinical signs of IBD appeared 2 days post-infection (dpi) and
declined by day 4 dpi due to the rapid recovery of survivors. At 2
dpi, moderate to severe clinical signs appeared among the mock-
immunized birds (group 9) and challenge control (group 11). Most
of the birds in the other groups developed mild clinical signs. At 3
dpi, mortality was observed among the mock-immunized birds
(group 9) and challenge control (group 11) as well as birds in
groups 5 and 6 that received 50 mg IBD-SVPs with and without
oral adjuvant. The other chickens in these groups showed severe
clinical signs of IBD. Other groups that were orally immunized
with cell-encapsulated antigens showed mild to moderate clinical
signs. Mortality was observed among these groups beginning 4 dpi
but with a lower incidence (two in group 1 and one in group 4)
than the mock-immunized and challenge control groups. Mild
clinical signs also appeared by 4 dpi in birds from groups 7 and 8,
which received 500 mg purified IBD-SVPs with and without oral
adjuvant, but they recovered by 5 dpi. In contrast, mortality and
moderate to severe clinical signs were observed in birds from
groups 5 and 6, which received 50 mg IBD-SVPs. At 5 dpi, the
survivors showed the first signs of recovery. These observations
indicate that oral immunization with either cell-encapsulated or
purified antigen is immunogenic but the potency of the resulting
immunity is dose and formulation-dependent. In oral delivery,
500 mg of purified IBD-SVPs inhibits clinical signs more
efficaciously than 50 mg of purified IBD-SVPs and even 250 mg
of yeast cells containing IBD-VP2 (equivalent to 4 mg of the
antigen).
Efficacy of protection against viral challenge
Chickens from all groups (except group 13) were challenged
with the classical IBDV strain MB3, and the post-challenge
analysis is summarized in Table 3. The BF/BW ratios for the
surviving chickens in groups 1–7 and those in the mock-vaccinated
(group 9) and unvaccinated controls (group 11) differed signifi-
cantly (p,0.05) from those in groups 8, 10, 12 and the
unchallenged group 13. This indicated that, among the orally-
vaccinated groups, only those receiving a high dose of the purified
vaccine with adjuvant (group 8) were protected to the same degree
as chickens administered with either attenuated virus or the
parenteral vaccine.
Bursa lesion scoring was carried out by comparing the
histopathology of BFs isolated from chickens that had died during
the experiment or that were killed at the end-point. The results
indicated that chickens vaccinated with a high dose of the purified
(group 8) or cell-encapsulated antigen (group 2) along with the
adjuvant, showed less bursal damage than the other groups of
orally-vaccinated chickens. Oral vaccination with either purified
IBD-SVPs or cell-encapsulated IBD-VP2 prevented virus replica-
tion in vivo with varying efficacy. We found that 500 mg of the
purified vaccine with adjuvant (group 8) achieved 60% viral
clearance whereas the parenteral and oral control vaccines
achieved 100% viral clearance.
The protection rate was 100% in the orally-vaccinated chickens
from groups 2, 3, 7 and 8, and also in those receiving the
intramuscular vaccine (group 10) and the live vaccine (group 12).
This indicated that the oral administration of purified and cell-
encapsulated IBD-SVPs is protective, although it does not
eliminate the virus as efficiently as the live vaccine or parenteral
IBD-SVPs.
Discussion
Vaccination is currently the most effective way to control IBDV,
and conventional vaccines are attenuated viruses based on mild or
intermediate strains [37] thus avoiding vaccination side effects
such as immunosuppression and clinical disease signs [1].
However, these vaccines are less effective against the diverse and
vv IBDV strains that have arisen more recently. Recombinant
subunit vaccines comprising the host-protective antigen (VP2)
from those strains could provide a suitable alternative, and the lack
of proliferation after vaccination would avoid the side effects
attributed to the live vaccine. A rapid and reliable large-scale
production platform is required to meet demand for vaccines
against circulating IBDV strains, and the yeast P. pastoris is a
simple and cost-effective eukaryotic platform for the production of
heterologous proteins which meets these criteria. Transgene
integration into the yeast genome allows the stable propagation
of recombinant host cells, allowing us to achieve yields of 76 mg
VP2 per liter of culture (16 mg/g of freeze-dried cells). Although
VP2 as a protective recombinant vaccine has already been
produced in other heterologous expression systems such as plants
[16,29], yeast [25,38] and insect cell lines [26,27,28] with various
degree of success, according to our knowledge the maximum
reported production level was 30 mg/l in High-Five cells [27].
The recombinant IBD-VP2 protein was designed to accumulate
in the cytosol, thus (i) preventing glycosylation in the secretory
pathway (which could induce a non-favorable immune response),
and (ii) encapsulating the antigen within the cell to provide
protection against the harsh acidic and proteolytic conditions in
the digestive tract following oral delivery. SDS-PAGE and
immunoblot analysis of protein extracts from the recombinant
yeast cells revealed the presence of a 40-kDa protein that was
detected with a VP2-specific antibody, and further analysis showed
that the IBD-VP2 subunits were aggregated into more immuno-
genic IBD-SVPs (Figure 3) that remains stable during heat
inactivation and freeze drying (Figure 4).
We found that P. pastoris provided a practical system for antigen
production and oral delivery to chickens. P. pastoris cells producing
VP2 have previously been administered to chickens by intramus-
cular injection and were shown to be safe and to confer protection
against IBDV [24]. We found that orally-administered heat-
inactivated yeast cells producing IBD-VP2 induced a protective
immune response against IBDV in chickens (Figure 5 and Table 2)
which increased survival rates to 60–100% compared to 40% in
the control groups. The oral delivery of 500 mg purified yeast-
derived antigen conferred 100% protection, which is much better
than the 10% protection previously achieved by oral immuniza-
tion with heat-inactivated but intact cells of the yeast Kluyveromyces
lactis, containing 1–3 mg IBD-VP2 [38]. In contrast, oral
immunization with transgenic rice grains containing 2–10 mg
VP2 conferred 83% protection [16]. The authors speculated that
the dose of VP2 provided by K. lactis cells was insufficient to induce
a potent immune response hence the low level of protection [38].
We found that 500 mg of purified yeast-derived IBD-SVPs was
more immunogenic and protective than 4 mg of encapsulated
VP2 and conferred full protection. We therefore concluded that
homogenization of the cells may be essential to release the antigen
and thus expose it to mucosal immunocompetent cells. It seems
that the chicken digestive system does not digest the yeast cell walls
rapidly enough to release the antigen. We also conclude that
unencapsulated, purified IBD-SVPs are stable enough in the
Protective Oral Vaccination against IBDV
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chicken digestive tract to resist degradation until they are taken by
M cells, which allows them to induce the immunocompetent cells
located beneath. This confirms our previous observation that IBD-
SVPs tolerate acidic conditions (pH 2.0) in vitro without becoming
denatured [30].
Although the oral delivery of VP2 was no better (in terms of
protection, clinical signs, BF/BW ratios and virus clearance) than
the current vaccination measures based on parenteral vaccination
with IBD-SVPs and oral vaccination with live vaccine, the oral
delivery of 500 mg purified IBD-SVPs conferred full protection
and (when administered with adjuvant) achieved 60% viral
clearance. This is promising because it suggests that oral adjuvants
can induce a cytotoxic T-cell response. An optimized formulation
and/or alternative adjuvants may improve the efficacy of the oral
vaccine. Importantly, the oral delivery of subunit vaccines is
quicker, safer and less expensive than parenteral vaccination
because expert personnel are not required and the process does
not cause stress in the chickens. In contrast to complete vaccines,
recombinant subunit vaccines allow discrimination between
infected and vaccinated animals (DIVA) based on the different
antibody responses against the vaccine and the whole virus.
Serological testing based on the detection of antibody responses
against virus proteins that are not found in the vaccine will
therefore facilitate the controlled eradication of the disease.
Subunit vaccines can also be used without damaging the disease-
free status of countries because discriminatory antibodies would
not interfere with disease surveillance by serological testing [39].
Protection against IBDV is highly dependent on the antigenic
correlation between the vaccine and the circulating virus strains
[40]. Although all identified IBD-VP2 amino acid sequences are
more than 93% identical, the variations between strains are
generally found within virus-neutralizing epitopes. Vaccination
with highly pathogenic strains confers protection against less
pathogenic challenge strains. However, the dose and strain of both
the vaccine and challenge virus affects the degree of protection
[41,42]. Cross-protection is useful for the development of vaccines
conferring protection against a broad spectrum of IBDV strains,
and we found that expressing IBD-VP2 derived from the vv strain
IR01 as a recombinant protein in yeast results in the assembly of
SVPs that protect chickens against the classical MB3 strain
following oral vaccination. The serological cross reactivity among
IBDV isolates may explain the observed protection. The vv strain
IR01 with Asian origin is more that 99% identical at amino acid
level to European strains. Therefore, the immunization and
challenge experiments reflect the situation in the field. However,
the immunological potency is dependent on dose and formulation,
and could be thus improved by the development of optimized
formulation strategies such as the homogenization of cell
preparations and/or the co-administration of alternative adju-
vants.
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